View Press Releases
-
MIB Agents’ Community of Families Has Awarded Over $1.9M in Grants to Research Pediatric Bone Cancer
-
Mage Biologics announces first subject dosed in a Phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease
Mage Biologics (“Mage”) announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for the treatment of inflammatory bowel disease (IBD).
Jun 11, 2024
-
Integrated DNA Technologies Announces New Primers and Probe Set to Identify H5N1 Avian Influenza
Integrated DNA Technologies today launched the Avian Influenza Type A (H5) Primers and Probe Set to enable researchers to identify, target, and trace the presence of clade 2.3.4.4b of the H5N1 virus across bird, environmental, dairy cow, and poultry farm samples.
Jun 10, 2024
-
CluePoints Brand Evolution Confirms Commitment to ‘Turning Artificial Intelligence into Human Intelligence’
CluePoints Brand Evolution Confirms Commitment to ‘Turning Artificial Intelligence into Human Intelligence’ CluePoints extends its use of AI/ML and continues to find smarter ways to manage clinical trials
Jun 11, 2024
-
CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT
CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT
Jun 11, 2024
-
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage
Exothera has announced that Asgard Therapeutics has selected them to develop and scale-up a manufacturing process for the viral vector-based immunotherapy candidate AT-108, including development of analytical methods, GMP-grade material production, and aseptic filling.
Jun 10, 2024
-
CordenPharma & Certest: A Powerful Partnership Unleashing the Potential of Patented Ionizable Lipids in LNP Formulation
-
City University of New York Partners with Genestack to Enhance AI readiness of Life Science Data in the Bioconductor Program
Genestack has announced a collaboration with City University of New York (CUNY) to streamline data curation for the BioConductor program, a widely used open-source software project that provides tools for the analysis and comprehension of high-throughput genomic data.
Jun 5, 2024
-
FDA and CluePoints Sign New 3 Year Cooperative Research and Development Agreement to Assess Data Quality using Statistical Modelling and Machine Learning
FDA extends its use of CluePoints to include AI/ML within an automated system to assess data quality in multicenter clinical trials
Jun 4, 2024
-
Syngene launches platform for rapid, enhanced protein production
-
Sinequa Augments Companies with Release of New Generative AI Assistants
Sinequa announces new AI Assistants; Combining Sinequa’s Search with GenAI provides the ultimate AI Assistant and virtual coworker
Jun 3, 2024
-
The varvis® Software: The First Genomics End-to-End Software Certified as IVDR Class C Device
We are pleased to announce that Limbus Medical Technologies GmbH, a medical device manufacturer and software development company based in Rostock, Germany, has reached a significant milestone in the field of genetic diagnostics. The varvis® software is now the first complete genomics software solution certified as a Class C device under the In-Vitro Diagnostic Regulation (IVDR) EU 2017/746.
May 31, 2024
-
Qlucore starts project after receiving prestigious EU grant to advance personalized cancer treatment
Qlucore to receive a prestigious EIC Accelerator grant of 2,5 million Euros to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer.
Jun 2, 2024
-
AES Clean Technology Announces Appointment of New CEO
-
4D Path Announces New Data Highlighting Efficacy of the Q-plasia OncoReader (QPOR) Platform
We wanted to reach out today with some exciting, breaking news. 4D Path, a company dedicated to personalizing cancer care through their advanced approach to predicting tumor response announced this morning new clinical data regarding the efficacy of their patented Q-Plasia OncoReader (QPOR) platform, highlighted in two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. "This is an exciting moment for oncology and pathology," said Stuart J. Schnitt, M.D., Chief of Breast Oncologic Pathology for the Dana-Farber Brigham Cancer Center, Associate Director of the Dana-Farber Cancer Institute/Brigham and Women's Hospital Breast Oncology Program. "The 4D Path QPOR Platform can potentially help inform researchers and clinicians about which patients are more or less likely to respond to neoadjuvant chemotherapy, paving the path for more precise and personalized treatments for patients." For the first time ever, we can unveil the dynamics of the tumor microenvironment, allowing biopharma and clinicians to get more targeted and precise in the development of therapies and treatment plans. Not only that, but the profound effects this will have on clinical trials and patient stratification, the benefits to pathologists and clinicians on the front lines with patients, and to patients – not only getting more targeted treatments but also helping the people who would have not responded, more effectively get to a treatment plan that might work. This is a monumental step forward in oncology. We would love to connect you with Satabhisa Mukhopadhyay, PHD, Chief Scientific Officer and Co-Founder of 4D Path, to provide more commentary regarding the importance of this moment and how their innovative, human approach (no AI, no machine learning) is allowing us to be more effective and specific when developing and implementing treatments. We would also be happy to discuss submitting an article authored by Satabhisa discussing these topics, and connect you with industry experts like Dr. Schnitt as well. We have placed below the press release for your reference. Please let us know if you have any questions. We are always available. Look forward to hearing from you.
May 29, 2024
-
Innovation and automation are driving forces behind next generation cell therapy manufacturing platform from Cytiva
-
PathAI Expands Portfolio of AI-Powered Products, Announcing PathExplore™ IOP and IHC Explore™ Ahead of ASCO 2024
PathAI, a global leader in AI-powered pathology, unveiled two novel AI products, PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore1™ to empower cancer drug developers and clinical researchers with AI-powered insights. The product pairing provides unprecedented single-cell and spatial resolution of the tumor microenvironment from routine pathology samples to facilitate biomarker discovery and deeper understanding of treatment response for the next generation of cancer therapeutics. The expansion of the Explore™ portfolio comes at a time when AI-pathology is experiencing accelerated large-scale adoption across the diagnostic and biopharma industries.
May 28, 2024
-
ZeOmega Names Tabatha Fuchs Chief Marketing and Communications Officer
-
Sakura Finetek Europe B.V. advances its laboratory automation with the Tissue-Tek xPrint® LP Laser Cassette Printer
Sakura Finetek Europe announces the launch of its newest advancement in tissue sample identification bringing laboratory workflows to the next level.
May 28, 2024
-
ResultsCX Achieves Coveted Great Place to Work® Certification™ Across Five Countries